Nuwellis (NUWE) Stock: Buy, Sell, or Hold?
NUWE - Nuwellis, Inc. Common Stock
$0.32
-0.17 (-33.97%)
▼
5d:
-41.31%
30d:
-60.09%
90d:
-83.81%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When NUWE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NUWE is down 41.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NUWE is down 41.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NUWE is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.55 to $0.85.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 34.0% recently.
Market Sentiment: NUWE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+3315.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 34.0% recently.
Market Sentiment: NUWE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+3315.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.55 -
$0.85
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-34.0%)
- BULLISH: Trading 3315.1% below Wall St target ($11.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.55 -
$0.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.32
Resistance Level
$0.71
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.51
Wall Street Target
$11.00
(+3315.1%)
Revenue Growth (YoY)
14.1%
Earnings Growth (YoY)
-99.2%
Profit Margin
-125.6%
Share & Embed Analysis
Last updated: October 24, 2026 1:32 AM ET
Data refreshes hourly during market hours. Next update: 2:32 AM
Data refreshes hourly during market hours. Next update: 2:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUWE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 46 HOLD |
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 41 HOLD |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 38 SELL |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 70 BUY |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$167 | 37 SELL |
